Table 2.
Hazard ratios for positive surgical margin outcomes following radical prostatectomy
| BCR
|
CRPC
|
Metastases
|
PC-specific mortality
|
Overall Survival
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
|
|
|
|
|
|
|||||||||||
| Margins | |||||||||||||||
| Crude | 2.58 | 2.31–2.88 | <0.001 | 2.01 | 1.38–2.93 | <0.001 | 2.00 | 1.43–2.78 | <0.001 | 2.21 | 1.43–3.44 | <0.001 | 1.06 | 0.93–1.21 | 0.370 |
| Adjusted* | 1.98 | 1.75–2.23 | <0.001 | 1.20 | 0.96–1.83 | 0.408 | 1.29 | 0.88–1.88 | 0.186 | 1.28 | 0.78–2.11 | 0.327 | 0.96 | 0.83–1.11 | 0.588 |
| Adjusted** | - | - | - | 1.19 | 0.78–1.82 | 0.425 | 1.29 | 0.89–1.89 | 0.184 | 1.28 | 0.78–2.11 | 0.328 | 0.97 | 0.84–1.13 | 0.700 |
HR are vs. negative surgical margins
BCR=biochemical recurrence; CRPC=castrate-resistant prostate cancer; CI=confidence interval
*
Adjusted for age, race, preoperative PSA, pathological Gleason score, seminal vesicle invasion, extracapsular extension, year of surgery, surgical center, and receipt of adjuvant therapy
**
Adjusted for age, race, preoperative PSA, pathological Gleason score, seminal vesicle invasion, extracapsular extension, year of surgery, surgical center, receipt of adjuvant therapy, and receipt of salvage radiation therapy (time-dependent)